Inventiva FY23 €(2.43) Vs €(1.31) YoY; Revenues For 2023 Amounted To €17.5 Million, Up By 43.4%, Compared To €12.2 Million In 2022
Portfolio Pulse from Benzinga Newsdesk
Inventiva reported a significant increase in its FY23 revenues to €17.5 million, up 43.4% from €12.2 million in 2022, driven by licensing agreements with CTTQ and Hepalys for the development of lanifibranor in MASH/NASH. However, the company's net loss widened to €110.4 million from €54.3 million due to increased R&D expenses, particularly for the NATiV3 Phase III clinical trial and the LEGEND Phase IIa trial. Cash and equivalents decreased to €26.9 million, with a material uncertainty regarding the company's ability to continue as a going concern. Inventiva received significant financing in 2023, including a €35.7 million capital increase and royalty certificates issuance, and upfront and milestone payments from CTTQ and Hepalys.
March 27, 2024 | 8:04 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Inventiva's FY23 report shows a revenue increase and significant financing activities, but a widened net loss and concerns about cash flow and going concern status.
The widened net loss and the explicit mention of a material uncertainty regarding the company's ability to continue as a going concern could negatively impact investor sentiment in the short term, despite the increase in revenue and successful financing activities. The significant R&D expenses and the decrease in cash and cash equivalents highlight the financial challenges Inventiva faces, potentially leading to downward pressure on the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100